for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oxford Immunotec Global PLC

OXFD.O

Latest Trade

13.10USD

Change

-0.83(-5.96%)

Volume

35,543

Today's Range

13.01

 - 

14.05

52 Week Range

8.37

 - 

17.77

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
13.93
Open
13.43
Volume
35,543
3M AVG Volume
5.04
Today's High
14.05
Today's Low
13.01
52 Week High
17.77
52 Week Low
8.37
Shares Out (MIL)
25.95
Market Cap (MIL)
339.37
Forward P/E
-21.52
Dividend (Yield %)
--

Next Event

Q2 2020 Oxford Immunotec Global PLC Earnings Call

Latest Developments

More

Oxford Immunotec Announces Agreement With Stop TB Partnership - Global Drug Facility

Oxford Immunotec Global Reports Q1 Revenue Of $13.9 Million

Oxford Immunotec Global Q1 Loss Per Share $0.23

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC,is a diagnostics company. It is focused on developing and commercializing tests for under-served immune-regulated conditions. Its product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Tick-borne disease is the collective name for diseases passed to humans through the bite of an infected tick. Its diagnostic tests for tick-borne infections include multiple laboratory developed tests (LDTs). Its tick-borne disease tests utilize molecular methods (such as polymerase chain reaction) and techniques to prosecute the immune system. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease.

Industry

Medical Equipment & Supplies

Contact Info

94C Innovation Drive

OX14 4RZ

United Kingdom

+44.1235.442780

http://www.oxfordimmunotec.com/north-america/company/about-us/

Executive Leadership

Patrick J. Balthrop

Independent Chairman of the Board

Peter James Wrighton-Smith

Chief Executive Officer, Director

Matthew T E McLaughlin

Chief Financial Officer

Janet Louise Kidd

General Counsel, Company Secretary

Ronald A. Andrews

Independent Director

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.1K

2018

0.1K

2019

0.1K

2020(E)

0.1K
EPS (USD)

2017

-2.190

2018

0.590

2019

-0.050

2020(E)

-0.608
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.66
Price To Book (MRQ)
1.71
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.02
LT Debt To Equity (MRQ)
0.02
Return on Investment (TTM)
-2.36
Return on Equity (TTM)
-2.20

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up